Greeting from the CEO
I believe that unless we try, it is very difficult to tell the success or failure of a bio-venture business. As a bio-veture, we can carry out research in more challenging fields that big pharma may hesitate to initiate. Our research focuses on miRNAs, whose working and regulatory mechanisms have not yet been well-understood. By exploring the activity and functions of miRNAs in various pathological processes, we aim to provide new solutions for treatment of incurable diseases and regenerative medicine.
Teruo Susumu Ph.D.
aceRNA Technologies, co., ltd.
Chief Executive Officer Dr. Teruo Susumu
Prof. Hirohide Saito (Vice director of Center for iPS cells Research and Applications, Kyoto University)
Dr. Nobuhiro Yagi (Kyoto University Innovation Capital co., ltd.)
|Date of Estabilshment||
Innovation Hub Kyoto, 46-29 Yoshidashimoadachi-cho, Sakyo-ku, Kyoto 606-8304, Japan
|Number of staff||
|5 Nov. 2019||
Successfully obtained Series A Funding!
|30 Jul. 2019||
Recieved the 'hosei-monodukuri' grant-in-aid.
|28 Jun. 2019||
Commenced sales of RNA Switch reagents for cell purification.
|19 Dec. 2018||
Recieved the 'Kigyounomori・Sangakunomori' promotion for business grant from Kyotosangyo 21.
|9 Nov. 2018||
Successfully obtained seed round funding!
|27 Sep. 2018||
Recieved the reseach & development grant from MitsubishiUFJ Technology Development Foundation.